Today’s antihyperglycemic drugs target a variety of pathological mechanisms implicated in T2DM, ranging from insulin secretion (e.g., SUs), peripheral glucose uptake (e.g., biguanides) and glucose reabsorption (e.g., SGLT2 inhibitors) (Chaudhury et al., 2017). This evidence concerns the gene INS and type 2 diabetes mellitus.